Olema Pharmaceuticals Inc (OLMA) FinancialsOLMAOlema Pharmaceuticals Inc

Evaluating the bottom line, Olema Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -52.74%, provide a clear picture of how effectively OLMA converts its operational activities into shareholder value.

In the context of the broader market, OLMA competes directly with industry leaders such as TBPH and ACRS. With a market capitalization of $944.10M, it holds a leading position in the sector. When comparing efficiency, OLMA's gross margin of N/A stands against TBPH's 100.00% and ACRS's 10.80%. Such benchmarking helps identify whether Olema Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Olema has reported consistent net losses, with a net income of -63.2 million USD in Q2 2026 and a negative EPS of -0.61, reflecting ongoing financial challenges. Despite a strong cash position of $505.3 million, the company is still not profitable, which raises concerns for long-term investors.